Medication info

Y2Rose Tab 20mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Seongyi Bio Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/box [15 tablets/PTP (Alu-Alu) x 2]
Approval status
Active

MFDS item code 202106981 · Approved 2021.10.18

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, treatment goals, and patient response. The dose may be increased to a maximum of 20 milligrams daily. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of a 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of a 40-milligram dose of this medicine is contraindicated in some of these patients.
Children's dosage
Age 10 years ~ age 17 years: The usual dose range is 5 milligrams ~ 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Safety and efficacy in children under 10 years of age have not been established.

Ingredients

Manufacturer
Seongyi Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • familial heterozygous hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is mainly used as an adjunctive therapy in patients with primary hypercholesterolemia and mixed dyslipidemia when diet and exercise are inadequate. It may also assist patients with homozygous familial hypercholesterolemia when combined with other lipid-lowering therapies. It lowers total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis, and is also used as an adjunct to diet in pediatric patients between the ages of 10 and 17 with heterozygous familial hypercholesterolemia. It aids in the dietary management of patients with primary dysbetalipoproteinemia. In particular, it is used to reduce the risk of stroke, myocardial infarction, and vascular revascularization in men over 50 years and women over 60 years who have elevated high-sensitivity C-reactive protein levels and other cardiovascular risk factors. Thus, this medication is effectively used in various dyslipidemia and cardiovascular disease risk groups.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, treatment goals, and patient response. The dose may be increased to a maximum of 20 milligrams daily. 3. Older adults: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of a 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of a 40-milligram dose of this medicine is contraindicated in some of these patients.

Children's dosage

Age 10 years ~ age 17 years: The usual dose range is 5 milligrams ~ 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Safety and efficacy in children under 10 years of age have not been established.

Precautions

This drug should not be used in patients with certain diseases or conditions. For example, patients who are allergic to any component of this drug, those with severely impaired liver function, muscle disorders, severe renal impairment, and women who are pregnant or breastfeeding should not take this medication. Furthermore, due to the potential for muscular side effects, it should be used cautiously in patients at high risk of muscle pain, myopathy, or rhabdomyolysis. Such patients should regularly undergo blood tests to monitor muscle enzyme levels. Patients with liver function abnormalities or a history of excessive alcohol consumption also require caution, and regular liver function tests should be conducted during treatment. This medication may raise blood glucose levels in some patients, so individuals at risk of diabetes should regularly check their blood sugar levels. Additionally, this drug may interact with other medications, so patients should inform their healthcare provider of any other medications being taken, especially those that carry a risk of muscle toxicity. Women who may become pregnant should use appropriate contraception, and this drug should not be used during pregnancy. Its use is also not recommended while breastfeeding. In cases of overdose, there is no specific antidote; thus, treatment should focus on symptom management, along with monitoring of liver function and muscle enzymes. If symptoms such as dizziness or muscle pain occur during treatment, patients should immediately consult their healthcare provider, and discontinue use if serious side effects are suspected.

Side effects

Angioedema, hypersensitivity reaction, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular muscle weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, drug-induced lichenoid eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain the storage temperature between 1 degree and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/box [15 tablets/PTP (Alu-Alu) x 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.